Skip to main content
Publications
Adelakun A, Dolph M, Matthews E, Oglebsy A, Campbell K, Davis A, Xu J, Hardy I, Danchenko N, Anderson SJ. Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada. Poster presented at the HIV Drug Therapy Glasgow 2024; November 10, 2024. Glasgow, Scotland. [abstract] J Int AIDS Soc. 2024 Nov; 27:234-5.
Percy AK, Neul JL, Benke TA, Berry-Kravis EM, Glaze DG, Marsh ED, Barrett AM, An D, Bishop KM, Youakim JM. Trofinetide for the treatment of Rett syndrome: long-term safety and efficacy results of the 32-month, open-label LILAC-2 study. Med. 2024 Oct 11;5(10):1275-1281. doi: 10.1016/j.medj.2024.06.007
Montgomery ET, Beksinska M, Mgodi N, Schwartz J, Weinrib R, Browne EN, Mphili N, Musara P, Jaggernath M, Ju S, Smit J, Chirenje ZM, Doncel GF, van der Straten A. End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study. J Int AIDS Soc. 2019 May;22(5):e25283. doi: 10.1002/jia2.25283.
van der Straten A, Agot K, Ahmed K, Weinrib R, Browne EN, Manenzhe K, Owino F, Schwartz J, Minnis A, TRIO Study Team. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J Int AIDS Soc. 2018 Mar;21(3):e25094. doi: 10.1002/jia2.25094